Targeted combination therapy triumphs in KRAS-positive metastatic colorectal cancer

MADRID — The combination of a KRAS G12C inhibitor and an EGFR inhibitor significantly improved progression-free survival (PFS) compared to standard of care in patients with chemotherapy-resistant metastatic colorectal cancer (mCRC). was shown in the randomized phase III CodeBreaK 300 trial. With a median follow-up of 7.8 months, median PFS was 5.6 months for patients […]